Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Lineage Cell Therapeutics, Inc. (LCTX)

$1.03 +3.32% NYSE: LCTX · 15-min delayed
  • CARLSBAD, California
  • Public · NYSE: LCTX
  • 77 employees
$256.8MMarket cap
$14.6MRevenue · FY2025
-$63.5MNet income
77Employees
LCTXNYSE
1992IPO

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Reported figures

Financial summary

Revenue FY2025
$14.6M
Net income
-$63.5M
Total assets
$112.6M
Market cap
$256.8M

Source: SEC EDGAR · updated Jun 7, 2026

NYSE: LCTX
$1.03 +3.32%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.90 $1.96

52-week range

Market cap
$256.8M
Shares outstanding
249.3M
Open
—
Day range
–
Prev close
—
Volume
—
IPO date
Mar 5, 1992

Lineage Cell Therapeutics, Inc. (LCTX) Stock Price

  • Reported a net loss of $63.5M in FY2025.
  • Trading 47% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Lineage Cell Therapeutics, Inc..

Write a review
Newsroom

News about Lineage Cell Therapeutics, Inc.

News & sentiment via Polygon.io

FAQ

Lineage Cell Therapeutics, Inc.: frequently asked questions

Is Lineage Cell Therapeutics, Inc. an American company?

Lineage Cell Therapeutics, Inc. is a US-based company headquartered in Carlsbad, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Lineage Cell Therapeutics, Inc. headquartered?

Lineage Cell Therapeutics, Inc. is headquartered in Carlsbad, California, United States.

Is Lineage Cell Therapeutics, Inc. publicly traded?

Yes — Lineage Cell Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol LCTX on the NYSE.

What does Lineage Cell Therapeutics, Inc. do?

Lineage Cell Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →